# CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)

> **NCT02825914** · NA · COMPLETED · sponsor: **University of Aarhus** · enrollment: 80 (actual)

## Conditions studied

- Colitis, Ulcerative
- Inflammatory Bowel Diseases

## Interventions

- **DIETARY_SUPPLEMENT:** Casein glycomacropeptide (CGMP)
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT02825914
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-01
- **Primary completion:** 2019-07-01
- **Final completion:** 2019-10-01
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02825914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02825914, "CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02825914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*